Minocycline is a semi-synthetic second-generation tetracycline antibiotic. Synthesized in 1967, it is a broad-spectrum antibiotic used in the management and treatment of many infectious and non-infectious diseases, with similar anti-infectious activity to that of other tetracyclines. Aside from anti-infectious activity against both gram-positive and gram-negative bacteria, it also has anti-inflammatory, anti-oxidant, anti-apoptotic, and immunomodulatory effects. It is known to be the most effective tetracycline derivative at providing neuroprotective effects, as it is a highly lipophilic molecule that can cross the blood-brain barrier.
Susceptibility to tetracycline is typically predictive of susceptibility to minocycline. Minocycline covers Borrelia recurrentis, Mycobacterium marinum, Mycoplasma pneumoniae, Staphylococcus aureus (including MRSA), Acinetobacter baumannii, Vibrio vulnificus, and susceptible strains of vancomycin-resistant enterococcus (VRE). Minocycline is also used to treat rickettsial infections, chlamydial infections, syphilis, pelvic inflammatory disease, acne, nocardiosis, brucellosis, ehrlichiosis, amebiasis, actinomycosis, anaplasmosis, leptospirosis, melioidosis, tularemia, traveler's diarrhea, Lyme disease (early stage), legionnaire's disease, and Whipple disease.
Nonantibiotic indications for minocycline include rosacea, bullous dermatoses, neutrophilic diseases, pyoderma gangrenosum, sarcoidosis, aortic aneurysms, cancer metastasis, periodontitis, as well as autoimmune disorders such as rheumatoid arthritis and scleroderma.
In both eukaryotic and prokaryotic cells, protein synthesis occurs through the use of ribosomes, which translate messenger RNA (mRNA) codes into functioning proteins. Prokaryotic cells use the 30S, and 50S subunits of ribosomes and eukaryotic cells use the 40S and 60S subunits of ribosomes. In both prokaryotic and eukaryotic organisms, the two ribosomal subunits combine at the mRNA template to allow for transfer RNA (tRNA) to bring an amino acid and form cellular proteins via elongation of amino acid chains.
Tetracyclines, and by extension minocycline, bind to the 30S ribosomal subunit, preventing the charged tRNA from bringing an amino acid to elongate the amino acid chain and form a cellular protein. Halting this process results in a bacteriostatic effect on the prokaryotic cell, wherein the organism can no longer grow or replicate.
Tetracyclines are lipid-soluble compounds capable of transportation across hydrophobic barriers such as biological membranes. Due to their lipophilicity, they are rapidly absorbed and distributed throughout the organism.
Minocycline is more lipophilic than other tetracyclines, such as doxycycline; thus, it achieves higher concentrations in the central nervous system (CNS) and skin.
Minocycline is available for administration in both oral and parenteral forms. Oral forms are absorbed in the stomach and proximal small intestine. Absorption rates are dependent on the presence of food, particularly products containing divalent cations such as calcium, which chelates minocycline and other tetracyclines rendering them unabsorbable. It can also be administered intravenously (IV). The IV route has seen use in the treatment of pneumonia, bloodstream infections, as well as skin and skin structure infections.
More common adverse effects of minocycline include gastrointestinal distress and photosensitivity. Hyperpigmentation of skin and discoloration of nails is also possible. Staining of teeth and bone growth inhibition is more likely to occur in children than adults, although it has been reported in adults as well. The prevalence of tooth discoloration due to minocycline is 3 to 6%.
Hepatotoxicity may occur due to minocycline use, and exacerbation of preexisting renal failure is also a risk to consider. Pill esophagitis - symptoms of which present as chest pain, odynophagia, and dysphagia - have also been reported and may be avoided by taking oral forms of minocycline with adequate water and standing upright after intake.
Although side effects are rare, the higher concentrations of minocycline in the CNS as compared to other tetracyclines are thought to contribute to the dose-limiting vestibular side effects (such as nausea, vomiting, vertigo, dizziness or change in hearing). Research has also found a correlation between tetracycline use and idiopathic intracranial hypertension (pseudotumor cerebri).
There is a reported association between systemic lupus erythematosus (SLE) with minocycline use (risk of 8.8 cases per 100,000 person-years). Tetracycline use also has correlations with drug-induced pancreatitis.
As with all antibiotics, minocycline increases the risk of developing Clostridium difficile infection; however, the risk is lower as compared to other antibiotics.
All tetracyclines can cross the placental barrier and are contraindicated in pregnancy, and this is no less true for minocycline. Due to their potential for permanent discoloration of teeth and impairment of long bone growth in the fetus, pregnant women should avoid tetracyclines. Hepatotoxicity in the pregnant mother is also a risk factor to consider and another reason not to use it.
Generally, any patients under the age of 16 should avoid using minocycline as the risk of permanent teeth discoloration in unerupted teeth is present. Ideally, avoid minocycline until after all crowns are complete (13 to 19 years).
Although most tetracycline group medication should be avoided in patients with chronic renal failure, minocycline elimination is independent of renal function. High doses of minocycline have been shown to increase urea excretion in healthy subjects. In patients with kidney impairment, On the other hand, aggravation of uremia may occur due to minocycline's catabolic effects. Therefore it is important to monitor both the therapeutic doses of minocycline and renal function in patients with renal failure to avoid further aggravation of uremia.
Long-term therapeutic dose of minocycline of up to 200 mg/day is generally safe and well-tolerated. Most adverse effects, such as nausea and dizziness, occur early after administration and disappear shortly after discontinuation of the medication. The recommendation is that after six months of minocycline treatment, all patients be monitored at three months interval for adverse effects such as hepatotoxicity, pigmentation, and SLE initiation or worsening.
Minocycline achieves peak serum concentrations ranging from 3 to 8.75 mg/L following 200 mg intravenous administration. The half-life of minocycline can range from 13 hours (dose and route: 200 mg orally single dose) to 21 hours (dose and route: 200 mg IV single dose). Serum concentration has been shown to have no relationship to renal function, and fecal elimination accounts for about 20 to 35% of the dose. Thus, the serum concentration and half-life of minocycline are not significantly affected by either renal impairment or end-stage renal disease.
Common adverse effects, as well as rarer autoimmune reactions and hepatotoxicity, warrants discontinuation of minocycline and switching to an antibiotic outside of the tetracycline class. It is important to note that minocycline carries a significantly higher risk of developing SLE as compared to other tetracyclines. Thus a high index of suspicion and immediate discontinuation of the medication and supportive measures is recommended if symptoms develop.
While minocycline use has decreased due to safety concerns such as irreversible pigmentation, high cost, and teratogenic effects, it is vital to understand both the indications and adverse effects when considering this medication. Increase antibiotic resistance in the community might make this antibiotic more useful and commonly prescribed again in the future.
Using targeted drug-susceptibility therapy will benefit not only the patient but also society as a whole. The entire healthcare team must work collaboratively to ensure that minocycline is the appropriate agent and that the patient understands both the risks and benefits of the medication. Patients should receive instruction from both the physician and pharmacist on what signs and symptoms to watch out for, as pertains to the possible adverse effects.
Collaboration within the health care team will improve both patient outcomes in terms of reducing adverse drug reactions, increase the likelihood of patient compliance to medication, and decrease morbidity and mortality.
|||Nagarakanti S,Bishburg E, Is Minocycline an Antiviral Agent? A Review of Current Literature. Basic [PubMed PMID: 26177421]|
|||Cunha BA,Sibley CM,Ristuccia AM, Doxycycline. Therapeutic drug monitoring. 1982; [PubMed PMID: 7048645]|
|||Shutter MC,Akhondi H, Tetracycline 2020 Jan; [PubMed PMID: 31751095]|
|||Sapadin AN,Fleischmajer R, Tetracyclines: nonantibiotic properties and their clinical implications. Journal of the American Academy of Dermatology. 2006 Feb; [PubMed PMID: 16443056]|
|||Garrido-Mesa N,Zarzuelo A,Gálvez J, Minocycline: far beyond an antibiotic. British journal of pharmacology. 2013 May; [PubMed PMID: 23441623]|
|||Chopra I,Roberts M, Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiology and molecular biology reviews : MMBR. 2001 Jun; [PubMed PMID: 11381101]|
|||Saivin S,Houin G, Clinical pharmacokinetics of doxycycline and minocycline. Clinical pharmacokinetics. 1988 Dec; [PubMed PMID: 3072140]|
|||Colton B,McConeghy KW,Schreckenberger PC,Danziger LH, I.V. minocycline revisited for infections caused by multidrug-resistant organisms. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016 Mar 1; [PubMed PMID: 26896499]|
|||Sánchez AR,Rogers RS 3rd,Sheridan PJ, Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. International journal of dermatology. 2004 Oct; [PubMed PMID: 15485524]|
|||Gordon G,Sparano BM,Iatropoulos MJ, Hyperpigmentation of the skin associated with minocycline therapy. Archives of dermatology. 1985 May; [PubMed PMID: 3158285]|
|||Smith K,Leyden JJ, Safety of doxycycline and minocycline: a systematic review. Clinical therapeutics. 2005 Sep; [PubMed PMID: 16291409]|
|||Jacobson JA,Daniel B, Vestibular reactions associated with minocycline. Antimicrobial agents and chemotherapy. 1975 Oct; [PubMed PMID: 1081373]|
|||Garner SE,Eady A,Bennett C,Newton JN,Thomas K,Popescu CM, Minocycline for acne vulgaris: efficacy and safety. The Cochrane database of systematic reviews. 2012 Aug 15; [PubMed PMID: 22895927]|
|||Jones MR,Hall OM,Kaye AM,Kaye AD, Drug-induced acute pancreatitis: a review. The Ochsner journal. 2015 Spring; [PubMed PMID: 25829880]|
|||Tariq R,Cho J,Kapoor S,Orenstein R,Singh S,Pardi DS,Khanna S, Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Feb 1; [PubMed PMID: 29401273]|
|||Demers P,Fraser D,Goldbloom RB,Haworth JC,LaRochelle J,MacLean R,Murray TK, Effects of tetracyclines on skeletal growth and dentition. A report by the Nutrition Committee of the Canadian Paediatric Society. Canadian Medical Association journal. 1968 Nov 2; [PubMed PMID: 4879536]|
|||Urban TJ,Nicoletti P,Chalasani N,Serrano J,Stolz A,Daly AK,Aithal GP,Dillon J,Navarro V,Odin J,Barnhart H,Ostrov D,Long N,Cirulli ET,Watkins PB,Fontana RJ, Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor. Journal of hepatology. 2017 Jul; [PubMed PMID: 28323125]|
|||Bhat G,Jordan J Jr,Sokalski S,Bajaj V,Marshall R,Berkelhammer C, Minocycline-induced hepatitis with autoimmune features and neutropenia. Journal of clinical gastroenterology. 1998 Jul; [PubMed PMID: 9706776]|
|||Raymond J,Cook D, Still leaving stains on teeth-the legacy of minocycline? The Australasian medical journal. 2015; [PubMed PMID: 26045724]|
|||Phillips ME,Eastwood JB,Curtis JR,Gower PC,De Wardener HE, Tetracycline poisoning in renal failure. British medical journal. 1974 Apr 20; [PubMed PMID: 4825113]|
|||Carney S,Butcher RA,Dawborn JK,Pattison G, Minocycline excretion and distribution in relation to renal function in man. Clinical and experimental pharmacology [PubMed PMID: 4459000]|
|||Agwuh KN,MacGowan A, Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. The Journal of antimicrobial chemotherapy. 2006 Aug; [PubMed PMID: 16816396]|
|||Bosch B,Mansell H, Interprofessional collaboration in health care: Lessons to be learned from competitive sports. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. 2015 Jul; [PubMed PMID: 26448769]|